Moderator: Jon Glaudemans

Senior Advisor, Sepsis Alliance & Founder, Payment Policy Analytics

Jon has 35+ years of experience in healthcare business, policy, and data analytics. He began his career at the White house budget office, then spent a decade at Aetna, initially as head of policy and business strategy, and then as the Market Leader for one of Aetna’s largest HMO/PPO markets. After serving at CMS and developing President Bush’s Drug Discount Program, Glaudemans returned to the policy arena in 2001, running the Washington DC office of an Austin-based lobbying and communication firm. He joined Avalere as Chief Operating Officer in 2005. From 2010-2012, Jon and his wife sailed their 44’ sailboat around the world. He then served as Chief Communications and Advocacy Officer for Ascension before returning to the East Coast to join Manatt Health. In 2017, Glaudemans served as CEO of United Rheumatology, a physician/GPO start-up, and in 2019, he returned to DC to found Payment Policy Analytics, providing advisory and analytic services to the healthcare market. Jon is a sepsis survivor, and is active with the Sepsis Alliance, which recognized him as a Sepsis Hero in 2017. He currently serves as Executive Advisor to the Sepsis Alliance Institute.

Jasmine Moore

Carly J. Worden, Pharm D, MPH

Senior Manager, Global Market Access, Health Economics & Policy, Danaher Corp., Diagnostics & Life Science Platforms

Dr. Carly J. Worden (AKA Carly J. Paoli, for publication purposes), PharmD, MPH, is a health economist with over 10 years of experience in both the pharmaceutical and medical devices/diagnostics industries. Dr. Worden has more than a dozen peer-reviewed manuscripts in epidemiology, burden of disease, real-world outcomes and health economics. She is a guest lecturer for advanced health economic studies at both the University of California, San Francisco and the University of Southern California. Since beginning her work at Danaher in 2016, she has been an integral team member for the Beckman Coulter hematology therapeutic area as a key subject matter expert in sepsis, producing two peer-reviewed manuscripts and winning an award for Best Industry Poster at AACC (American Association of Clinical Chemistry) 2019.

Shelby D. Reed, PhD, RPh

Professor, Population Health Sciences and Medicine, Duke University School of Medicine; Director, Center for Informing Health Decisions, Duke Clinical Research Institute

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University, Faculty Leader of the Center for Informing Health Decisions, and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has over 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs, and patient-centered interventions. Her research currently focuses on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of ISPOR in 2017-2018.

Kevin Schulman, MD

Professor of Medicine, School of Medicine, Professor of Economics (by Courtesy), Graduate School of Business, Stanford University

Dr. Schulman was appointed as Professor of Medicine, Associate Chair of Business Development and Strategy in the Department of Medicine, Director of Industry Partnerships and Education for the Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and, by courtesy, Professor of Economics at Stanford’s Graduate School of Business in June, 2018. Dr. Schulman’s research interests include organizational innovation in health care, health care policy and health economics. With over 300 original articles, 80 review articles/commentaries, and 40 case studies/book chapters, Kevin Schulman has had a broad impact on health policy (h-index = 69). His peer-reviewed articles have appeared in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. He is a member of the editorial/advisory boards of the American Heart Journal, Health Policy, Management and Innovation (www.HMPI.Org), and Senior Associate Editor of Health Services Research.

Mikie Sherrill, MSc, JD

Congresswoman, New Jersey’s 11th Congressional District

Congresswoman Mikie Sherrill proudly represents New Jersey’s 11th Congressional District. After graduating from the United States Naval Academy in 1994, she spent almost 10 years on active duty in the United States Navy. She flew missions throughout Europe and the Middle East as a Sea King helicopter pilot, worked on the Battle Watch Floor in the European Theater during the Iraq invasion, and served as a Flag Aide to the Deputy Commander in Chief of the U.S. Atlantic Fleet. Congresswoman Sherrill also served as a Russian policy officer and worked on the implementation of our nuclear treaty obligations and oversaw the relationship between the U.S. Navy and Russian Federation Navy. She attended law school after leaving the Navy, earning a degree from Georgetown University. She worked as a lawyer and eventually joined the U.S. Attorney’s Office in New Jersey. As an Outreach and Re-entry Coordinator, Congresswoman Sherrill developed programs to help prevent crime in the community. These programs developed trust between law enforcement and the communities they serve, and helped people leaving prison to gain employment, housing, and education in order to restart their lives. As an Assistant U.S. Attorney, she worked to keep our communities safe, prosecuting federal cases and advising law enforcement on investigations.